ACTH for treatment of acute respiratory distress syndrome
View Patent ↗Provided herein are methods of treatment of acute respiratory distress syndrome comprising administration of adrenocorticotropic hormone (ACTH). or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.
1. A method of treating an individual diagnosed with or suspected of having acute respiratory distress syndrome (ARDS) comprising administration of a therapeutically effective amount of an adrenocorticotropic hormone (ACTH) peptide to an individual in need thereof, wherein the ACTH peptide is an ACTH 1-39 peptide having the sequence:
(SEQ ID NO: 1)
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
1 2 3 4 5 6 7 8 9 10
Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
11 12 13 14 15 16 17 18 19 20
Lys-Val-Tyr-Pro-X aa1 -Gly-Ala-Glu-Asp-X aa2 -
21 22 23 24 25 26 27 28 29 30
Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH
31 32 33 34 35 36 37 38 39
wherein X aa1 is Asp or Asn; and X aa2 is Gln or Glu.
2. The method of claim 1 , wherein the ACTH peptide is administered in an initial phase of from one to five doses at daily intervals and a subsequent phase of one or more doses administered at intervals greater than one day.
3. The method of claim 2 , wherein each of the one to five doses of the initial phase is between about 10 U and about 100 U.
4. The method of claim 2 , wherein each of the one or more doses of the subsequent phase is between about 30 U and about 100 U.
5. The method of claim 2 , wherein each of the one to five doses of the initial phase is between about 30 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 20% and about 100% of each of the one to five doses of the initial phase.
6. The method of claim 2 , wherein each of the one to five doses of the initial phase is between about 45 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 10 U and about 80 U.
7. The method of claim 2 , wherein each of the one to five doses of the initial phase is between about 60 U and about 100 U, and each of the one or more doses of the subsequent phase is between about 20 U and about 60 U.
8. The method of claim 2 wherein each of the one to five doses of the initial phase is about 64 U, and each of the one or more doses of the subsequent phase is about 32 U.
9. The method of claim 8 , wherein the one or more doses of the subsequent phase are administered at intervals selected from the group consisting of every two days, every three days, every four days, every 5 days, every 6 days, once a week, and every two weeks.
10. The method of claim 1 , wherein the ACTH peptide is formulated as an injectable solution, immediate release formulation, prolonged release formulation, controlled release formulation, delayed release formulation, pulsatile release formulation, multiparticulate formulation or mixed immediate and controlled release formulation.
11. The method of claim 1 , wherein the ACTH peptide is formulated as a gel.
12. The method of claim 10 , wherein the ACTH peptide is administered intramuscularly, subcutaneously, intravenously, systemically, transmucosally, parenterally, intranasally, buccally, transdermally, rectally, by inhalation or by implant.
13. The method of claim 11 , wherein the ACTH peptide is administered by injection intramuscularly.
14. The method claim 1 , wherein the ACTH peptide is administered intravenously.
15. The method of claim 1 , wherein the ACTH peptide is a recombinant ACTH peptide.
16. The method of claim 1 , wherein the ACTH peptide is a porcine-derived ACTH peptide.
17. The method of claim 1 , wherein the ACTH peptide is a synthetic ACTH peptide.
18. The method of claim 1 , further comprising administration of a second therapeutic treatment, wherein the second therapeutic treatment is administered sequentially or simultaneously.
19. The method of claim 18 , wherein the second therapeutic treatment is ventilation, a glucocorticoid, a surfactant, inhaled nitric oxide, an antioxidant, a protease inhibitor, a recombinant human activated protein C, a β2-agonist, lisofylline, a statin, inhaled heparin, a diuretic, a sedative, an analgesic, a muscle relaxant, an antibiotic, inhaled prostacyclin, inhaled synthetic prostacyclin analog, ketoconazole, alprostadil, keratinocyte growth factor, a beta-agonist, human monoclonal antibody (mAb) against tissue factor Vila (TS factor 7a), an interferon receptor agonist, insulin, perfluorocarbon, budesonide, recombinant human angiotensin-converting enzyme (ACE), recombinant human Clara cell 10 kDa (CC10) protein, tissue plasminogen activator, human mesenchymal stem cells, or nutritional therapy.
20. The method of claim 18 , wherein the second therapeutic treatment is methylprednisolone, dexamethasone, prednisone, prednisolone, betamethasone, triamcinolone, triamcinolone acetonide, beclometasone, albuterol, lisofylline, rosuvastatin, inhaled heparin, inhaled nitric oxide, recombinant human activated protein C, ibuprofen, naproxen, acetaminophen, cisatracurium besylate, procysteine, acetylcysteine, inhaled prostacyclin, ketoconazole, alprostadil, keratinocyte growth factor, a beta-agonist, human monoclonal antibody (mAb) against tissue factor Vila (TS factor 7a), insulin, perfluorocarbon, budesonide, recombinant human angiotensin-converting enzyme (ACE), recombinant human Clara cell 10 kDa (CC10) protein, tissue plasminogen activator, human mesenchymal stem cells, nutritional therapy, a combination of omega-3 fatty acids, an antioxidant, γ-linolenic acids with isocaloric foods, or mechanical ventilation.
21. The method of claim 1 , wherein the ACTH peptide is SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.